Medtronic PLC vs Royal Caribbean Cruises Ltd — how do they compare? Medtronic PLC trades at $88.48 (market cap $112.24B), while Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| MDT | RCL | |
|---|---|---|
Market Cap | $112.24B | $75.26B |
Volume | 105,663,236 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $348.03 |
52-Week Low | $73.75 | $230.30 |
Typical Hold Time | 63 Days | 85 Days |
Enterprise Value | $131.58B | $97.91B |
Dividend Yield | 3.28% | 2.13% |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Royal Caribbean (RCL) trades at $281.39, showing modest daily weakness but maintaining strong bullish momentum with analyst consensus pointing to significant upside. The company demonstrates robust fundamentals with revenue growth from $8.8B in 2022 to $17.9B in 2025, net income margin expanding to 23.54%, and positive cash flow generation. Recent developments include a $3B investment in Sandals Resorts and strong Q2 2026 earnings beat, while technical indicators show the stock trading near key resistance levels with overall bullish signals.
RCL presents compelling investment potential with 23% upside to consensus price target of $346.67, supported by strong earnings momentum and expanding profitability. However, risks include elevated debt levels, execution challenges from the Sandals acquisition, and sensitivity to fuel price volatility. The stock's current valuation at 17.38x P/E appears reasonable given the company's growth trajectory and industry-leading margins.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →